title: Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.
abstract: We aimed to investigate the association between incretin-based therapies and 1-year change in depressive symptoms in a cohort of 1735 patients with newly diagnosed type 2 diabetes. The incretin group experienced significant reduction in depressive symptoms compared to controls. This was independent of HbA1c and may be mediated by an anti-inflammatory mechanism.
authors.affiliation: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: calum.moulton@kcl.ac.uk.
authors.forename: C D
authors.initials: CD
authors.lastname: Moulton
authors.affiliation: Diabetes and Nutritional Sciences Division, King's College London, London, UK.
authors.forename: J C
authors.initials: JC
authors.lastname: Pickup
authors.affiliation: Diabetes and Nutritional Sciences Division, King's College London, London, UK.
authors.forename: S A
authors.initials: SA
authors.lastname: Amiel
authors.affiliation: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Winkley
authors.affiliation: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Ismail
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D003863:Depression / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000009:adverse effects / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood; D008131:London; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; D007004:Hypoglycemic Agents; D054795:Incretins; D018836:Inflammation Mediators; D002097:C-Reactive Protein
keywords: Depressive symptoms; Incretin-based therapies; Inflammation; Type 2 diabetes